Breaking News

Clondalkin Group Appoints CEO

February 4, 2013

Lennon to head global business development plans

David Lennon has been appointed global chief executive officer of the Pharmaceutical and Healthcare Division at Clondalkin Group. Mr. Lennon will head Clondalkin’s global business development plans and will work closely with the European and North American management teams. The division has invested almost $300 million during the past five years and plans to significantly increase the international packaging group’s geographical footprint and expand its current product offering.
 
Mr. Lennon joined the company in 2009 as chief executive officer of the European Pharma and Healthcare division. Mr. Lennon was responsible for the expansion of accredited pharmaceutical packaging facilities from three to eight sites through growth and strategic acquisition.
 
Clondalkin Group chief executive Norbert McDermott said, “We appointed David in 2009 because his pedigree as a senior executive as well as his packaging business expertise was clear.  In his four years with Clondalkin Group he has continued to prove himself to be an invaluable leader in consolidating our position as a leading producer of secondary pharmaceutical packaging where we now operate from 18 sites in North America and Europe. I am delighted to have David heading up the global development strategy of our Pharmaceutical and Healthcare Division and am confident of our continued success.”

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016